Related Experiment Video
Updated: Aug 13, 2026

Isolation of Pulmonary Artery Smooth Muscle Cells from Neonatal Mice
Published on: October 20, 2013
Persistent pulmonary hypertension of the newborn. An update
1Department of Pediatrics, UVa Health Sciences Center, Charlottesville 22908.
Abstract:
PPHN remains a perplexing and frustrating disorder for primary care physicians and neonatologists. The diagnosis is difficult and the optimal management controversial. ECMO has become a lifesaving technological advance for infants who do not respond to conventional medical management, and neurodevelopmental outcome of infants treated with ECMO has been favorable. The most recent therapy with potential usefulness is inhaled nitric oxide which allows local vasodilator effects without unwanted systemic effects. Inhaled nitric oxide therapy for PPHN is still in the clinical trial phase and results of these trials will direct future use.
More Related Videos
Related Concept Videos
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
Pulmonary Embolism I: Introduction
Pulmonary Embolism III: Nursing Management
Pulmonary Embolism I: Introduction

